EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.

Research paper by Hsiang-Fong HF Kao, Chia-Chi CC Lin, James Chih-Hsin JC Yang

Indexed on: 11 Jul '13Published on: 11 Jul '13Published in: Future oncology (London, England)


Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC.